ongo
problem
emerg
antimicrobi
resist
liken
balloon
settl
one
specif
issu
result
bulg
even
wors
problem
howev
much
learn
best
use
critic
antibacteri
agent
way
avoid
even
repair
resist
damag
done
compil
current
literatur
strongli
suggest
slow
develop
resist
antimicrobi
agent
optim
use
drug
one
mechan
action
target
prescrib
demonstr
abil
minimis
revers
resist
problem
avoid
underdos
potent
antibiot
recent
inform
also
indic
best
limit
empir
use
blactam
plu
fluoroquinolon
combin
therapi
sinc
two
class
activ
common
resist
respons
use
togeth
facilit
multidrug
resist
import
pathogen
particularli
pseudomona
aeruginosa
acinetobact
speci
review
discuss
role
major
antimicrobi
class
resist
develop
present
specif
strategi
combat
grow
problem
multidrugresist
bacteria
knowledg
better
manag
antimicrobi
agent
prescrib
practic
find
resourc
appli
understand
remain
formid
challeng
begin
centuri
accompani
appear
increas
number
emerg
infecti
diseas
truli
new
eg
sever
acut
respiratori
syndrom
sar
other
caus
old
microb
possess
new
resist
phenotyp
multidrugresist
pseudomona
aeruginosa
acinetobact
spp
toxin
communityacquir
methicillinresist
staphylococcu
aureu
pantonvalentin
leukocidin
toxin
gene
pass
three
distinct
era
last
yearsmov
preantibiot
era
antibiot
era
era
emerg
infecti
diseas
mani
question
worthi
consider
tri
understand
occur
better
cope
infecti
diseas
person
global
front
new
antimicrobi
agent
introduc
even
fewer
discoveri
stage
critic
question
ask
whether
prescrib
practic
improv
revers
least
retard
portion
emerg
infect
problem
selfinflict
suboptim
use
avail
antimicrobi
agent
purpos
review
make
critic
assess
glean
current
evid
suggest
might
practic
done
slow
process
bacteria
develop
multidrug
resist
year
ago
dr
harold
neu
sound
alarm
increas
antibiot
resist
recent
report
progress
pathogen
mcgeer
correctli
point
antibiot
pressur
provid
crucial
facilit
role
dissemin
well
develop
resist
thu
import
focu
better
use
antimicrobi
agent
must
assess
impact
major
antibacteri
class
develop
resist
relat
compound
well
explor
impact
one
class
antimicrobi
agent
may
enhanc
resist
unrel
drug
muchdiscuss
writtenabout
topic
great
major
evid
indic
import
healthcar
issu
least
publish
data
clearli
suggest
peopl
admit
hospit
antibioticresist
bacteri
infect
much
less
like
receiv
proper
initi
therapi
associ
costlier
hospit
stay
consider
evid
also
confirm
mortal
rate
higher
patient
given
earli
therapi
activ
infect
microb
even
consid
problem
threat
entir
healthcar
system
surpris
bacteria
readili
adapt
antibiot
exposur
sinc
exist
thrive
least
billion
year
excel
schemat
present
emerg
spread
resist
found
dutch
work
parti
antibiot
polici
websit
resist
clearli
begin
antibiot
exposur
even
one
two
bacteri
cell
surviv
opportun
develop
resist
strain
subsequ
newli
resist
microb
pass
person
person
amplifi
potenti
epidem
proport
dissemin
facilit
imperfect
infect
control
practic
antimicrobi
use
larg
number
peopl
permit
resist
pathogen
spread
among
person
diminish
protect
normal
flora
thu
improv
use
antimicrobi
agent
provid
least
two
opportun
better
manag
emerg
spread
resist
first
opportun
improv
select
drug
dose
regimen
minimis
microb
abil
surviv
thu
prevent
initi
develop
resist
second
opportun
use
agent
limit
spread
healthcareassoci
infecti
diseas
microbi
resist
prevent
come
refer
collater
damag
consider
data
avail
aspect
facilit
wise
choic
use
antimicrobi
chemotherapi
throughout
last
decad
antibiot
use
mani
idea
arisen
help
practition
better
prescrib
agent
includ
develop
practic
guidelin
improv
treatment
uniform
control
restrict
use
base
expert
decisionmak
econom
factor
profession
educ
nation
guidelin
reput
policymak
recommend
prudent
use
practic
antibiot
stepdown
prescrib
cycl
howev
date
none
notic
impact
problem
hand
futur
improv
diagnost
inform
system
offer
promis
still
year
away
last
decad
much
inform
appear
medic
literatur
regard
impact
specif
drug
class
emerg
dissemin
occasion
revers
problem
relat
antibiot
resist
spread
healthcareassoci
pathogen
use
inform
help
us
enhanc
effect
prescrib
limit
ongo
develop
spread
microbi
resist
addit
field
pharmacodynam
learn
much
actual
administr
antimicrobi
agent
either
benefici
detriment
knowledg
appli
today
late
austin
et
al
publish
articl
model
rise
antibiot
resist
scope
remedi
need
revers
problem
valid
base
observ
finland
iceland
core
find
drug
drug
class
level
use
exceed
eventu
lead
resist
occur
dramat
reduct
drug
prescrib
need
revers
trend
toward
increas
resist
gener
appear
use
exceed
defin
daili
dose
ddd
per
patient
popul
resist
would
typic
occur
timepoint
revers
major
reduct
use
much
achiev
level
antimicrobi
agent
resist
threshold
gener
ddd
patient
would
need
hospit
set
usual
denomin
use
patientday
one
assum
typic
cours
antibiot
therapi
day
ddd
patientday
convert
patient
receiv
given
drug
drug
class
hospit
nurs
unit
given
timean
exceedingli
small
amount
today
healthcar
environ
review
recent
report
nation
antimicrobi
consumpt
accompani
resist
problem
instruct
first
step
understand
current
resist
trend
neuhaus
et
al
report
larg
investig
record
chang
bacteri
suscept
intens
care
unit
icu
across
usa
record
suscept
result
nearli
gramneg
bacilli
along
consumpt
fluoroquinolon
geograph
area
surround
particip
hospit
administr
fluoroquinolon
increas
observ
increas
resist
variou
agent
quinolon
gentamicin
ceftazidim
ampicillinsulbactam
cefotaxim
ceftriaxon
ticarcillinclavulan
imipenem
piperacillintazobactam
would
suggest
threshold
reach
fluoroquinolon
use
overprescrib
class
increas
resist
mani
gramneg
bacteria
fluoroquinolon
agent
inform
regard
antibiot
use
bacteri
resist
netherland
also
enlighten
use
amoxicillinclavulan
rose
ddd
patientday
repres
high
level
use
base
austin
calcul
fluoroquinolon
use
also
increas
ddd
patientday
interestingli
signific
increas
resist
seen
fluoroquinolon
klebsiella
pneumonia
p
aeruginosa
escherichia
coli
aureu
macrolid
aureu
streptococcu
pneumonia
author
note
preced
year
use
macrolid
fluoroquinolon
netherland
hospit
doubl
data
suggest
threshold
increas
fluoroquinolon
macrolid
resist
surpass
well
also
note
aspect
minimis
multidrug
resist
develop
observ
amount
extendedspectrum
cephalosporin
nonsuscept
e
coli
netherland
remain
less
one
lowest
level
europ
rais
possibl
use
blactamasestabilis
antibiot
amoxycillinclavulan
commonli
use
inject
agent
netherland
hospit
may
prone
facilit
emerg
spread
resist
compound
fluoroquinolon
macrolid
class
third
studi
uk
assess
chang
piperacillintazobactam
activ
year
drug
introduc
chang
activ
p
aeruginosa
suscept
proteu
spp
year
problem
detect
resist
rose
e
coli
klebsiella
spp
ampcinduc
enterobacteriacea
howev
inform
concern
drug
use
provid
difficult
assess
agent
may
respons
chang
final
exampl
nation
antimicrobi
agent
inject
usag
data
avail
malaysia
administ
antibiot
extendedspectrum
cephalosporin
anoth
carbapenem
class
fluoroquinolon
data
obtain
im
retail
provid
perspect
plymouth
meet
pa
usa
major
problem
report
icu
patient
infect
cephalosporinresist
acinetobact
spp
repres
nearli
isol
nearli
klebsiella
spp
strain
e
coli
also
resist
extendedspectrum
cephalosporin
importantli
total
inject
antibiot
given
cefoperazonesulbactam
recommend
use
low
dosag
g
everi
h
lead
articl
written
year
earlier
demonstr
cefoperazon
adequ
dose
achiev
standard
suscept
breakpoint
g
l
administ
activ
drug
must
given
dose
g
everi
h
inform
suggest
predomin
use
broadspectrum
cephalosporin
particularli
potent
entiti
given
low
dose
strong
potenti
facilit
emerg
mani
bacteri
strain
resist
entir
class
antimicrobi
agent
consider
variat
use
antimicrobi
agent
across
world
even
within
geograph
area
close
social
econom
tie
european
union
order
start
devis
plan
alter
prescrib
practic
one
first
need
know
problem
face
local
ration
plan
improv
develop
necessari
implement
part
prescrib
physician
achiev
follow
evid
recent
literatur
agent
class
drug
contribut
emerg
spread
resist
accompani
exampl
work
clinic
practic
stabilis
revers
problem
basic
scienc
also
ad
understand
certain
chemic
compound
may
problemat
comment
upon
whenev
appropri
limit
number
antimicrobi
drug
class
use
treatment
infecti
diseas
within
hospit
set
includ
aminoglycosid
carbapenem
cephalosporin
fluoroquinolon
penicillin
vancomycin
also
grow
applic
new
compound
linezolid
quinupristindalfopristin
reserv
specif
limit
indic
instruct
review
applic
experi
concern
impact
use
therapeut
class
aminoglycosid
avail
sinc
earli
onset
antibiot
era
streptomycin
report
resist
mediat
sever
mechan
rang
efflux
impair
uptak
target
modif
enzym
inactiv
howev
littl
evid
aminoglycosid
mediat
resist
drug
class
even
impact
resist
drug
wellknown
capac
exhibit
synergist
activ
cell
wallact
agent
gerd
et
al
report
experi
rotat
cycl
gentamicin
amikacin
manag
problem
emerg
resist
enterobacteriacea
gentamicin
cycl
abl
switch
use
gentamicin
ddd
patientday
fewer
tenfold
decreas
amikacin
cycl
period
year
saw
desir
chang
increas
suscept
gentamicin
report
observ
effect
aminoglycosid
suscept
hospit
bacteria
similar
result
obtain
compar
studi
done
belgium
larg
addit
evalu
aminoglycosid
prescrib
us
hospit
also
provid
find
consist
gerd
et
al
switch
amikacin
provid
improv
aminoglycosid
activ
gramneg
pathogen
includ
p
aeruginosa
klebsiella
serratia
proteu
spp
experi
indic
littl
impact
aminoglycosid
suscept
bacteria
agent
clear
effect
drug
consumpt
resist
within
class
antibiot
also
show
problem
signific
resist
gentamicin
tobramycin
chang
cycl
amikacin
year
reestablish
suscept
aminoglycosid
imipenem
meropenem
consid
two
agent
widest
antibacteri
spectrum
avail
antibiot
class
due
consider
blactamas
stabil
earli
recognis
permeabilitymedi
resist
import
carbapenem
class
particularli
organ
p
aeruginosa
acinetobact
spp
zincdepend
carbapenemas
potent
inactiv
enzym
mediat
resist
carbapenem
date
remain
limit
import
presenc
bacteri
speci
despit
broad
spectrum
activ
antibiot
class
initi
public
associ
balloon
concept
antibiot
resist
aros
studi
imipenem
substitut
cephalosporin
order
reduc
rate
occurr
cephalosporinresist
k
pneumonia
rahal
et
al
abl
reduc
ceftazidim
use
cefotetan
use
accompani
increas
imipenem
prescrib
author
effort
succeed
reduc
occurr
cephalosporinresist
klebsiella
spp
observ
increas
imipenemresist
p
aeruginosa
within
medic
centr
burk
argu
improv
activ
klebsiella
spp
may
push
antibiot
balloon
result
outcom
resist
p
aeruginosa
give
overal
result
less
help
desir
major
current
problem
use
carbapenem
antibiot
constitut
highli
resist
gramneg
pathogen
repres
p
aeruginosa
acinetobact
spp
encompass
multipl
mode
develop
resist
import
mechan
probabl
upregul
efflux
particularli
associ
loss
outermembran
permeabl
protein
porin
oprd
complic
resist
class
fact
oprd
coregul
efflux
system
mexefoprn
select
fluoroquinolon
select
gener
fluoroquinolon
even
without
exposur
carbapenem
strain
p
aeruginosa
resist
fluoroquinolon
imipenem
also
reduc
suscept
resist
meropenem
increas
number
acquir
carbapenemas
found
p
aeruginosa
acinetobact
spp
add
grow
carbapenem
resist
problem
acinetobact
baumannii
becom
resid
healthcar
set
import
risk
factor
acquisit
carbapenemresist
strain
treatment
one
agent
also
carbapenemresist
acinetobact
spp
present
region
bacteria
propens
spread
throughout
geograph
area
overal
data
support
conclus
carbapenem
suscept
fairli
rapid
resist
develop
lead
spread
carbapenemresist
strain
p
aeruginosa
baumannii
frequent
use
clinic
set
highlevel
use
resist
also
occur
genera
citrobact
spp
discuss
detail
later
also
strong
implic
fluoroquinolon
select
joint
quinolonecarbapenem
resist
microbi
genera
thu
contribut
problem
carbapenem
multidrug
resist
p
aeruginosa
acinetobact
spp
recent
data
nation
nosocomi
infect
surveil
nni
system
highlight
problem
increas
carbapenem
resist
p
aeruginosa
pool
mean
carbapenem
use
nonicu
inpati
area
januari
june
rang
ddd
patientday
care
area
mean
fluoroquinolon
use
rang
ddd
patientday
despit
fact
use
carbapenem
well
expect
engend
emerg
resist
rang
p
aeruginosa
strain
resist
imipenem
surprisingli
averag
rang
isol
also
resist
ciprofloxacinlevofloxacin
inform
strongli
reinforc
concept
carbapenem
resist
microb
acinetobact
spp
p
aeruginosa
like
caus
overus
fluoroquinolon
upregul
efflux
system
export
quinolon
carbapenem
extendedspectrum
cephalosporin
come
use
wide
varieti
clinic
set
current
avail
agent
penetr
cerebrospin
fluid
signific
advantag
past
treatment
bacteri
mening
consid
good
clinic
efficaci
well
low
rate
sideeffect
thu
becom
agent
choic
mani
infecti
diseas
bacteri
respons
exposur
agent
activ
key
synthet
pathway
cell
wall
synthesi
multifacet
bacteria
particularli
gramneg
bacilli
produc
chromosom
plasmidmedi
resist
enzym
blactamas
continu
grow
number
phenotyp
express
bacteria
p
aeruginosa
acinetobact
spp
limit
drug
penetr
shed
porin
upregul
efflux
pump
complementari
blactamas
product
lead
effect
high
level
resist
much
seen
carbapenem
like
combin
mechan
import
gramneg
bacteria
lesser
greater
extent
acinetobact
spp
also
natur
compet
remodel
target
site
ad
resist
mechan
us
hospit
extendedspectrum
cephalosporin
appear
frequent
prescrib
antimicrobi
agent
averag
ddd
patientday
use
nonicu
area
mean
use
icu
set
rang
ddd
patientday
extrem
high
level
use
surpris
icu
set
resist
p
aeruginosa
enterobact
spp
reach
respect
even
inconsist
screen
extendedspectrum
blactamas
esbl
product
resist
k
pneumonia
exce
directli
relat
consequ
excess
use
agent
indic
grow
problem
esblproduc
enterobacteriacea
baumannii
resist
multipl
antibiot
class
unfortun
use
extendedspectrum
cephalosporin
also
becom
associ
collater
damag
facilit
infect
due
methicillinresist
aureu
mrsa
vancomycinresist
enterococci
vre
one
associ
link
ticarcillinclavulan
behav
set
like
cephalosporin
activ
enterococci
persist
problem
clostridium
difficileassoci
diarrhoea
cdad
also
relat
cephalosporin
prescrib
benefit
lower
cephalosporin
use
demonstr
penicillin
receiv
attent
recent
research
trial
compris
group
combin
agent
part
antibiot
includ
blactamas
inhibitor
drug
clavulan
sulbactam
tazobactam
addit
potent
inhibitor
ambler
class
plasmidmedi
blactamas
shown
contribut
addit
effect
bind
accessori
penicillinbind
protein
key
target
penicillin
compound
addit
properti
includ
enhanc
kill
mrsa
compar
vancomycin
invivo
anim
model
better
invitro
bactericid
activ
gramneg
gramposit
bacteria
augment
intracellular
kill
nonblactamaseproduc
bacteria
neutrophil
leukocyt
evid
multifactori
action
blactam
blactamas
inhibitor
compound
mind
surpris
becom
recognis
import
agent
battl
emerg
resist
clinic
use
agent
present
best
evid
role
combat
bacteri
resist
note
earlier
use
netherland
high
accompani
increas
resist
develop
howev
importantli
mani
investig
demonstr
util
use
compound
revers
problem
esbl
vre
cdad
extens
studi
use
agent
may
even
help
better
manag
increas
preval
mrsa
evidenc
fact
first
patient
infect
vancomycininsensit
mrsa
actual
cure
administr
ampicillinsulbactam
extens
publish
clinic
experi
concern
substitut
one
agent
extendedspectrum
cephalosporin
reduc
preval
esblproduc
bacteria
two
studi
particularli
worth
highlight
first
et
al
replac
thirdgener
cephalosporin
imipenemcilastatin
piperacillintazobactam
show
abl
maintain
cephalosporin
use
ddd
patientday
rate
esblproduc
bacteria
fell
second
studi
bantar
et
al
use
piperacillintazobactam
replac
thirdgener
cephalosporin
intervent
reduc
high
level
esblproduc
k
pneumonia
set
prior
switch
cefepim
fail
provid
desir
effect
lower
ceftazidim
ceftriaxon
use
ddd
patientday
ddd
patientday
respect
wherea
overal
prescrib
piperacillintazobactam
rose
ddd
patientday
rate
esblproduc
k
pneumonia
drop
interestingli
resist
p
aeruginosa
piperacillintazobactam
also
fell
despit
heavi
use
agent
impact
use
blactamas
inhibitor
compound
also
investig
manag
vre
studi
publish
investig
antibiot
cycl
deal
gramposit
pathogen
interest
intervent
bradley
et
al
replac
ceftazidim
piperacillintazobactam
cycl
back
ceftazidim
use
also
accompani
antibiot
intervent
enhanc
infect
control
programm
implement
expand
infect
control
programm
replac
extend
cephalosporin
use
blactamas
inhibitor
drug
reduc
rate
colonis
vre
complet
elimin
clinic
infect
howev
upon
switch
back
ceftazidim
rate
colonis
vre
rose
clinic
infect
reappear
patient
care
nurs
unit
also
noteworthi
increas
colonis
vre
return
clinic
infect
multidrugresist
pathogen
took
month
switch
back
ceftazidim
impli
cycl
strategi
minimis
problem
microb
use
support
prospect
trial
observ
studi
donskey
et
al
demonstr
protect
effect
acquisit
vre
receipt
ampicillinsulbactam
piperacillintazobactam
vs
increas
risk
infect
administr
cephalosporin
ticarcillinclavulan
result
similar
bradley
et
al
report
recent
articl
kolar
et
al
final
context
prospect
clinic
trial
demonstr
util
blactamas
inhibitor
compound
manag
healthcareassoci
infecti
diseas
cdad
settl
et
al
perform
welldesign
crossov
studi
compar
impact
cefotaxim
piperacillintazobactam
use
preval
import
healthcar
pathogen
demonstr
statist
signific
reduct
colonis
infect
piperacillintazobactam
arm
studi
rate
colonis
nearli
fourfold
lower
piperacillintazobactam
infect
reduc
nearli
tenfold
compar
cefotaxim
importantli
trial
support
larg
retrospect
observ
investig
demonstr
low
associ
ticarcillinclavulan
develop
cdad
case
nearli
dose
administ
compar
extendedspectrum
cephalosporin
case
dose
given
thu
demonstr
risk
associ
receiv
cephalosporin
vs
blactamas
inhibitor
combin
compound
result
settl
et
al
reinforc
experi
wilcox
et
al
chang
cefotaxim
piperacillintazobactam
use
back
cefotaxim
inhibitor
combin
becam
temporarili
unavail
initi
switch
cefotaxim
use
curtail
cdad
rate
fell
reintroduct
cefotaxim
rose
support
replac
cephalosporin
prescrib
piperacillintazobactam
effect
strategi
reduc
overal
burden
cdad
fluoroquinolon
import
antimicrobi
agent
treatment
seriou
infect
act
directli
bacteri
chromosom
lethal
effect
microbi
replic
process
unfortun
overus
associ
myriad
emerg
resist
consequ
directli
affect
fluoroquinolon
class
other
impact
resist
emerg
infect
unanticip
way
one
recent
recognis
critic
mechan
resist
result
induct
effluxpump
activ
known
fluoroquinolon
select
mutant
gramneg
bacteria
overproduc
wide
varieti
efflux
pump
singl
step
caus
resist
practic
class
antimicrobi
agent
grow
concern
problem
appar
caus
heavi
use
agent
associ
increas
resist
agent
carbapenem
resist
p
aeruginosa
sinc
fluoroquinolon
turn
sever
multidrugefflux
system
also
affect
carbapenem
heavi
use
agent
hospit
facilit
develop
multidrugresist
p
aeruginosa
leav
littl
avail
therapi
treatment
infect
recent
match
casecontrol
studi
investig
role
antimicrobi
therapi
acquisit
multidrugresist
p
aeruginosa
support
invitro
scienc
implic
prior
receipt
fluoroquinolon
major
independ
risk
factor
emerg
pathogen
accumul
evid
indic
best
avoid
use
fluoroquinolon
blactam
combin
empir
therapi
seriou
infect
one
begin
treatment
blactam
plu
aminoglycosid
two
agent
desir
first
h
either
discontinu
aminoglycosid
cultur
neg
chang
specif
therapi
organ
identif
suscept
known
signific
reduct
fluoroquinolon
use
achiev
littl
risk
aminoglycosid
nephrotox
need
therapeut
drug
monitor
fluoroquinolon
like
antimicrobi
agent
directli
influenc
level
resist
mani
bacteri
speci
evidenc
larg
surveil
studi
last
year
demonstr
introduct
second
agent
quinolon
class
hospit
set
accompani
increas
prescrib
rapidli
led
increas
fluoroquinolon
resist
p
aeruginosa
importantli
withdraw
less
activ
agent
lower
overal
use
possibl
achiev
revers
resist
trend
support
find
recent
report
paladino
et
al
demonstr
treatment
weakerpot
fluoroquinolon
predispos
later
infect
quinoloneresist
p
aeruginosa
newer
fluoroquinolon
agent
less
suscept
efflux
older
compound
remain
learn
preferenti
use
agent
moxifloxacin
especi
gramposit
pathogen
slow
futur
develop
resist
import
antimicrobi
class
one
current
major
concern
aris
use
fluoroquinolon
antimicrobi
agent
concept
collater
damag
enhanc
spread
drugresist
pathogen
first
glanc
seem
associ
administr
offend
compound
addit
concern
agent
caus
resist
blactam
gramneg
bacteria
recent
report
link
spread
mrsa
fluoroquinolon
prescrib
increas
preval
cdad
link
use
levofloxacin
gatifloxacin
harbarth
et
al
found
prior
receipt
fluoroquinolon
independ
risk
factor
persist
mrsa
carriag
failur
mupirocin
decolonis
even
absenc
highlevel
mupirocin
resist
graffund
venezia
also
report
quinolon
levofloxacin
exposur
independ
associ
mrsa
infect
odd
ratio
larg
casecontrol
studi
patient
similar
find
recent
describ
weber
et
al
investig
even
suggest
mechan
facilit
mrsa
colonis
exposur
fluoroquinolon
recal
bisognano
et
al
demonstr
ciprofloxacin
exposur
lead
increas
express
adher
factor
promot
host
colonis
aureu
signific
chang
adhes
exhibit
strain
grown
presenc
mic
quinolon
level
exposur
would
expect
case
mrsa
sinc
mrsa
strain
larg
resist
avail
fluoroquinolon
concept
could
also
explain
persist
colonis
note
earlier
harbarth
et
al
cdad
recent
come
associ
fluoroquinolon
prescrib
mccusker
et
al
found
greatest
associ
levofloxacin
prescrib
gayn
et
al
track
outbreak
switch
levofloxacin
gatifloxacin
use
editori
gerd
implic
fluoroquinolon
use
caus
emerg
resist
yet
anoth
microbi
pathogen
c
difficil
turn
lead
spread
organ
among
patient
within
hospit
environ
clear
high
level
fluoroquinolon
use
lead
sever
differ
advers
consequ
care
surveil
detect
problem
thought
plan
deal
healthcar
provid
effect
manag
consequ
vancomycin
natur
occur
antibiot
market
year
agent
consid
bactericid
gramposit
bacteri
speci
activ
gramneg
pathogen
bulki
action
antimicrobi
agent
involv
block
synthet
enzym
access
acyldaladala
portion
peptidoglycan
precursor
thu
stop
complet
cell
wall
structur
main
resist
vancomycin
directli
relat
use
slow
emerg
requir
nearli
year
launch
vancomycin
first
vancomycinresist
enterococci
appear
appear
impact
antimicrobi
class
associ
use
vancomycin
newest
inject
antimicrobi
class
oxazolidinon
repres
linezolid
streptogramin
quinupristindalfopristin
current
avail
member
compound
new
therapeut
scene
advers
resist
implic
result
use
overus
determin
howev
histori
teacher
us
need
remain
vigil
watch
unexpect
consequ
introduct
welcom
new
compound
primari
goal
antibiot
treatment
cure
patient
infect
avoid
resist
secondari
best
mind
prescrib
physician
last
decad
learn
much
theoret
practic
pharmacodynam
approach
prescrib
help
achiev
first
goal
exampl
clear
ratio
peak
drug
concentr
mic
infect
pathogen
maximis
bacteri
kill
aminoglycosid
therefor
dose
done
singl
daili
administr
also
understand
ratio
rate
follow
convent
recommend
infecti
diseas
societi
america
evid
support
recommend
b
high
level
indic
resist
exceed
recov
strain
c
reduct
repres
lower
prescrib
least
base
defin
daili
dose
ddd
patientday
goal
use
less
ddd
patientday
like
offend
agent
note
use
problem
detect
ddd
patientday
affect
agent
class
like
respons
resist
problem
area
serum
concentr
curv
auc
mic
relat
success
therapi
fluoroquinolon
macrolid
ketolid
glycopeptid
time
mic
best
predict
treatment
success
blactam
tetracyclin
oxazolidinon
understand
must
appli
patient
also
overal
prescrib
stewardship
import
drug
battl
facilit
resist
exampl
potent
agent
cefoperazonesulbactam
routin
prescrib
less
onequart
requir
dose
gramneg
pathogen
area
malaysia
india
author
unpublish
data
surpris
high
level
multidrugresist
pathogen
emerg
practic
toler
physician
encourag
pharmaceut
industri
much
use
inform
limit
avoid
even
revers
resist
antimicrobi
agent
becom
avail
last
decad
bulk
literatur
appear
suggest
sever
critic
option
import
first
step
perform
local
surveil
understand
problem
face
one
practic
area
problem
recognis
wellevidenc
step
taken
slow
even
revers
develop
resist
tabl
list
current
import
resist
problem
along
potenti
solut
document
rate
well
propos
intervent
investig
rate
follow
recommend
develop
infecti
diseas
societi
america
guidelin
rate
use
explain
tabl
gener
base
review
slow
develop
resist
antimicrobi
agent
current
literatur
strongli
suggest
use
agent
one
mechan
action
target
use
agent
demonstr
abil
minimis
resist
avoid
combin
blactam
fluoroquinolon
empir
therapi
gramneg
pathogen
avoid
underdos
potent
antibiot
conclus
year
experi
prescrib
antimicrobi
compound
much
insight
gain
describ
point
use
antimicrobi
drug
mcgeer
quot
goeth
seem
appropri
know
enough
must
appli
will
enough
must
futur
infecti
diseas
manag
us
good
evid
support
recommend
b
moder
evid
support
recommend
c
poor
evid
support
recommend
qualiti
evid
evid
least
one
properli
design
prospect
clinic
trial
well
addit
corrobor
retrospect
analys
ii
evid
one
cohort
casecontrol
analyt
studi
multipl
timeseri
may
support
result
uncontrol
observ
iii
evid
opinion
respect
author
base
clinic
experi
descript
studi
report
expert
committe
